Carla Weismantel
Psychiatric/Mental Health · Milwaukee, WINPI 1760111256
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 24.8% of the total. 2025 is the largest year on record at $2,132, more than ten times the $21 reported in 2023.
Across 144 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$666
- Supernus Pharmaceuticals, Inc.$418
- Axsome Therapeutics, Inc.$371
- Neos Therapeutics, LP$225
- Johnson & Johnson$225
- Alkermes, Inc.$184
- plus $592 from 9 others
What the payments were for
- Food & beverage$2,682100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $666 |
| Supernus Pharmaceuticals, Inc. | 29 | $418 |
| Axsome Therapeutics, Inc. | 17 | $371 |
| Neos Therapeutics, LP | 15 | $225 |
| Johnson & Johnson | 10 | $225 |
| Alkermes, Inc. | 8 | $184 |
| Collegium Pharmaceutical, Inc. | 12 | $153 |
| AbbVie | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Corium, LLC | 6 | $72 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Indivior Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,682 in reported general payments places this provider in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 26 | $567 |
| Buspirone Hcl | 38 | $483 |
| Duloxetine Hcl | 23 | $261 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $218 |
| Trazodone Hcl | 24 | $147 |
| Gabapentin | 14 | $139 |
| Fluoxetine Hcl | 16 | $89 |
| Citalopram HbrCitalopram Hydrobromide | 18 | $79 |
| Lorazepam | 11 | $74 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Milwaukee
- Carolyn DavidsonMilwaukee$46K
- Sherry AleksichMilwaukee$33K
- Ngozi ObioraMilwaukee$19K
- Victoria McGinleyMilwaukee$9K
- Andrea MitchellMilwaukee$6K
- Angeline VercauterenMilwaukee$6K
- Lisa CwiklaMilwaukee$5K
- Julia JasterMilwaukee$5K
- Angelia Felton-WilksMilwaukee$4K
- Kristen AndersonMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.